Sevelamer hydrochloride
Sponsors
Genzyme, a Sanofi Company, Shire, Astellas Pharma Inc, The University of Hong Kong, Vifor Pharma
Conditions
Chronic Kidney DiseaseChronic Kidney Disease, Stage 5Chronic Kidney FailureEnd Stage Renal DiseaseEndstage Renal DiseaseHemodialysisHyperphosphatemiaIntimal Media Thickness
Phase 2
Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing
CompletedNCT00324376
Start: 2003-03-31End: 2004-05-31Target: 24Updated: 2015-03-05
A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
CompletedNCT00505037
Start: 2007-10-31End: 2008-09-30Updated: 2011-03-22
Study of Phosphate Levels in Patients With Chronic Kidney Disease
CompletedNCT00824460
Start: 2008-12-31End: 2010-03-31Updated: 2014-04-01
Phase 3
Head to Head Study Against Sevelamer Hydrochloride
CompletedNCT00441545
Start: 2007-01-05End: 2008-07-31Updated: 2021-06-11
Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride
TerminatedNCT00844662
Start: 2009-07-31End: 2011-10-31Target: 1000Updated: 2010-10-19
A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
CompletedNCT01057407
Start: 2010-01-31End: 2010-09-30Updated: 2015-05-04
A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
CompletedNCT01850602
Start: 2013-04-23End: 2013-12-10Updated: 2018-10-09
Phase 4
Unknown Phase
Sevelamer Hydrochloride in Peritoneal Dialysis Patients
CompletedNCT00745589
Start: 2008-07-31End: 2015-01-31Updated: 2020-06-18
Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease
CompletedNCT01049815
Start: 2005-02-28End: 2009-02-28Updated: 2010-01-14